Kalaris Therapeutics Inc(KLRS)

Biotechnology · Berkeley Heights, NJ

$2.66-0.17 (-6.01%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

PE Ratio: N/A

Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/E ratio is N/A as of 2026-10-06T21:42:07.376Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:42:07.376Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote price: 2.66
Unrounded diluted TTM EPS · period ending 2026-06-30: -2.02

FMP input reference: 93c5e63ae445a2e41424364838d154d4df2cbb6a4085a726ee5a5ae15b1ce67b

Forward PE Ratio|PEG Ratio|P/B Ratio|EPS|All Metrics

KLRS PE Ratio Metrics

PE RATIO

N/A

KLRS Competitors' PE Ratio

KLRS

Kalaris Therapeutics Inc

Current

Market Cap

$58.06M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INKT

MiNK Therapeutics, Inc.

vs KLRS

Market Cap

$58.29M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BOLD

Boundless Bio, Inc.

vs KLRS

Market Cap

$57.76M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACET

Adicet Bio, Inc.

vs KLRS

Market Cap

$58.43M

PE Ratio

N/A

TTM Avg

110.41

3Y Avg

110.41

5Y Avg

110.41

PDSB

PDS Biotechnology Corporation

vs KLRS

Market Cap

$58.44M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TLPH

Talphera, Inc.

vs KLRS

Market Cap

$57.61M

PE Ratio

N/A

TTM Avg

0.43

3Y Avg

0.43

5Y Avg

0.43

CNTB

Connect Biopharma Holdings Limited

vs KLRS

Market Cap

$57.01M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

XLO

Xilio Therapeutics, Inc.

vs KLRS

Market Cap

$59.18M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ONCY

Oncolytics Biotech Inc.

vs KLRS

Market Cap

$60.02M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OKYO

OKYO Pharma Limited

vs KLRS

Market Cap

$56.02M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
Kalaris Therapeutics Inc (KLRS)	$58.06M	N/A	N/A	N/A	N/A
MiNK Therapeutics, Inc. (INKT)vs ›	$58.29M	N/A	N/A	N/A	N/A
Boundless Bio, Inc. (BOLD)vs ›	$57.76M	N/A	N/A	N/A	N/A
Adicet Bio, Inc. (ACET)vs ›	$58.43M	N/A	110.41	110.41	110.41
PDS Biotechnology Corporation (PDSB)vs ›	$58.44M	N/A	N/A	N/A	N/A
Talphera, Inc. (TLPH)vs ›	$57.61M	N/A	0.43	0.43	0.43
Connect Biopharma Holdings Limited (CNTB)vs ›	$57.01M	N/A	N/A	N/A	N/A
Xilio Therapeutics, Inc. (XLO)vs ›	$59.18M	N/A	N/A	N/A	N/A
Oncolytics Biotech Inc. (ONCY)vs ›	$60.02M	N/A	N/A	N/A	N/A
OKYO Pharma Limited (OKYO)vs ›	$56.02M	N/A	N/A	N/A	N/A

P/E Comparison

Trailing P/E

N/A

Forward P/E

N/A

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$2.66

Forward EPS (Est.)

$-2.01

Forward P/E

N/A

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

See the Lowest P/E Ratio Stocks ranking →

PE Ratio: N/A

KLRS PE Ratio Metrics

KLRS Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics